Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Inspired Question · S5W-35514 · Session 5

What action it is taking following the Medicines and Healthcare Products Regulatory Agency's (MHRA) review of the use of UK plasma for frac…

Answered Arranged question: government announcement Asked by David Torrance SNP Lodged 24 Feb 2021

The question

To ask the Scottish Government what action it is taking following the Medicines and Healthcare Products Regulatory Agency's (MHRA) review of the use of UK plasma for fractionation.

The answer

Answered by Mairi Gougeon on 25 Feb 2021 · 1 day after it was lodged, on time

The Medicines and Healthcare products Regulatory Agency has advised Ministers that, following its detailed review in 2020, the Commission on Human Medicines has recommended that UK plasma can be used for production of immunoglobulin medicines as they are satisfied that the risk of transmission of variant CJD (vCJD) via immunoglobulins manufactured from UK plasma is now negligible. The MHRA is now the sole regulator for medicines and the agency responsible for the licensing of medicinal products in the UK.
For this reason, Ministers across the UK have agreed to lift the current ban on using UK plasma for fractionation, which was introduced in 1998 as a vCJD risk mitigation measure. All other existing vCJD risk mitigation measures will remain in place.
This means plasma from donations given in the UK will now be able to be used to produce medicinal immunoglobulin products to treat patients in Scotland and the rest of the UK. This should improve the security of supplies of these medicines in future.
The Scottish Government will now work closely with the Scottish National Blood Transfusion Service to review options for the collection and use of plasma from donors in Scotland in future.

In the Official Report

No contribution in the Official Report cites S5W-35514 by reference.